Application of niclosamide in treatment of toxoplasmosis
The invention discloses an application of niclosamide in treatment of toxoplasmosis. The median inhibitory concentration of niclosamide on human foreskin fibroblasts is 8.3 [mu]g/ml. When the concentration of niclosamide in a culture medium is more than 100 ng/mL, the invasion of an insect body can...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LI BING ZHOU XUZHENG ZHANG JIYU SI HONGFEI CHENG FUSHENG ZHANG JILI |
| description | The invention discloses an application of niclosamide in treatment of toxoplasmosis. The median inhibitory concentration of niclosamide on human foreskin fibroblasts is 8.3 [mu]g/ml. When the concentration of niclosamide in a culture medium is more than 100 ng/mL, the invasion of an insect body can be completely inhibited in a dose-dependent manner. When the concentration of niclosamide increases,the number of cysts and tachyzoites in treatment holes and the average number of larvae in worm vesicles decrease in a dose-dependent manner. The median inhibitory concentration EC50 value of niclosamide on toxoplasma tachyzoite is 45.3 ng/ml; niclosamide can be used for treating toxoplasmosis by oral and intragastric administration. Niclosamide can inhibit the invasion and intracellular replication of toxoplasma tachyzoite and protect mice acutely infected with toxoplasma gondii. The ultrastructural observation shows that the inhibition effect of niclosamide on toxoplasma gondii can be related to the oxidative phosp |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN110478356A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN110478356A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN110478356A3</originalsourceid><addsrcrecordid>eNrjZLBwLCjIyUxOLMnMz1PIT1PIy0zOyS9OzM1MSVXIzFMoKUpNLMlNzSsByZXkV-QX5CQW5-YXZxbzMLCmJeYUp_JCaW4GRTfXEGcP3dSC_PjU4oLE5NS81JJ4Zz9DQwMTcwtjUzNHY2LUAABAli7b</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application of niclosamide in treatment of toxoplasmosis</title><source>esp@cenet</source><creator>LI BING ; ZHOU XUZHENG ; ZHANG JIYU ; SI HONGFEI ; CHENG FUSHENG ; ZHANG JILI</creator><creatorcontrib>LI BING ; ZHOU XUZHENG ; ZHANG JIYU ; SI HONGFEI ; CHENG FUSHENG ; ZHANG JILI</creatorcontrib><description>The invention discloses an application of niclosamide in treatment of toxoplasmosis. The median inhibitory concentration of niclosamide on human foreskin fibroblasts is 8.3 [mu]g/ml. When the concentration of niclosamide in a culture medium is more than 100 ng/mL, the invasion of an insect body can be completely inhibited in a dose-dependent manner. When the concentration of niclosamide increases,the number of cysts and tachyzoites in treatment holes and the average number of larvae in worm vesicles decrease in a dose-dependent manner. The median inhibitory concentration EC50 value of niclosamide on toxoplasma tachyzoite is 45.3 ng/ml; niclosamide can be used for treating toxoplasmosis by oral and intragastric administration. Niclosamide can inhibit the invasion and intracellular replication of toxoplasma tachyzoite and protect mice acutely infected with toxoplasma gondii. The ultrastructural observation shows that the inhibition effect of niclosamide on toxoplasma gondii can be related to the oxidative phosp</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191122&DB=EPODOC&CC=CN&NR=110478356A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191122&DB=EPODOC&CC=CN&NR=110478356A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LI BING</creatorcontrib><creatorcontrib>ZHOU XUZHENG</creatorcontrib><creatorcontrib>ZHANG JIYU</creatorcontrib><creatorcontrib>SI HONGFEI</creatorcontrib><creatorcontrib>CHENG FUSHENG</creatorcontrib><creatorcontrib>ZHANG JILI</creatorcontrib><title>Application of niclosamide in treatment of toxoplasmosis</title><description>The invention discloses an application of niclosamide in treatment of toxoplasmosis. The median inhibitory concentration of niclosamide on human foreskin fibroblasts is 8.3 [mu]g/ml. When the concentration of niclosamide in a culture medium is more than 100 ng/mL, the invasion of an insect body can be completely inhibited in a dose-dependent manner. When the concentration of niclosamide increases,the number of cysts and tachyzoites in treatment holes and the average number of larvae in worm vesicles decrease in a dose-dependent manner. The median inhibitory concentration EC50 value of niclosamide on toxoplasma tachyzoite is 45.3 ng/ml; niclosamide can be used for treating toxoplasmosis by oral and intragastric administration. Niclosamide can inhibit the invasion and intracellular replication of toxoplasma tachyzoite and protect mice acutely infected with toxoplasma gondii. The ultrastructural observation shows that the inhibition effect of niclosamide on toxoplasma gondii can be related to the oxidative phosp</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLBwLCjIyUxOLMnMz1PIT1PIy0zOyS9OzM1MSVXIzFMoKUpNLMlNzSsByZXkV-QX5CQW5-YXZxbzMLCmJeYUp_JCaW4GRTfXEGcP3dSC_PjU4oLE5NS81JJ4Zz9DQwMTcwtjUzNHY2LUAABAli7b</recordid><startdate>20191122</startdate><enddate>20191122</enddate><creator>LI BING</creator><creator>ZHOU XUZHENG</creator><creator>ZHANG JIYU</creator><creator>SI HONGFEI</creator><creator>CHENG FUSHENG</creator><creator>ZHANG JILI</creator><scope>EVB</scope></search><sort><creationdate>20191122</creationdate><title>Application of niclosamide in treatment of toxoplasmosis</title><author>LI BING ; ZHOU XUZHENG ; ZHANG JIYU ; SI HONGFEI ; CHENG FUSHENG ; ZHANG JILI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN110478356A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2019</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>LI BING</creatorcontrib><creatorcontrib>ZHOU XUZHENG</creatorcontrib><creatorcontrib>ZHANG JIYU</creatorcontrib><creatorcontrib>SI HONGFEI</creatorcontrib><creatorcontrib>CHENG FUSHENG</creatorcontrib><creatorcontrib>ZHANG JILI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LI BING</au><au>ZHOU XUZHENG</au><au>ZHANG JIYU</au><au>SI HONGFEI</au><au>CHENG FUSHENG</au><au>ZHANG JILI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application of niclosamide in treatment of toxoplasmosis</title><date>2019-11-22</date><risdate>2019</risdate><abstract>The invention discloses an application of niclosamide in treatment of toxoplasmosis. The median inhibitory concentration of niclosamide on human foreskin fibroblasts is 8.3 [mu]g/ml. When the concentration of niclosamide in a culture medium is more than 100 ng/mL, the invasion of an insect body can be completely inhibited in a dose-dependent manner. When the concentration of niclosamide increases,the number of cysts and tachyzoites in treatment holes and the average number of larvae in worm vesicles decrease in a dose-dependent manner. The median inhibitory concentration EC50 value of niclosamide on toxoplasma tachyzoite is 45.3 ng/ml; niclosamide can be used for treating toxoplasmosis by oral and intragastric administration. Niclosamide can inhibit the invasion and intracellular replication of toxoplasma tachyzoite and protect mice acutely infected with toxoplasma gondii. The ultrastructural observation shows that the inhibition effect of niclosamide on toxoplasma gondii can be related to the oxidative phosp</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN110478356A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Application of niclosamide in treatment of toxoplasmosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T20%3A06%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LI%20BING&rft.date=2019-11-22&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN110478356A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |